According to Cytiva’s 2023 Global Biopharma Resilience Index, the manufacturing of biologics in India is likely to increase over the next three years...
Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the su...
The agreement covers all 27 countries of the European Union, the UK, Australia, Canada, and New Zealand. Under terms of the agreement, Alvotech will receiv...
Roquette, a global leader in plant-based ingredients and a leading provider of pharmaceutical and nutraceutical excipients, is set to unveil its extensive ...
“We know that our customers need to provide novel, reliable and consistent products to their consumers and patients,” said Angela Strzelecki, p...
Amphista Therapeutics (“the Company” or “Amphista”), a leader in next generation targeted protein degradation (TPD) approaches, tod...
In today’s evolving industrial landscape, the concept of Industry 4.0 is revolutionizing various sectors by leveraging digitalization and automation ...
Astrea Bioseparations (“Astrea Bio”), a leading provider of high-quality bioseparation and purification technologies that help to improve patie...
AI-powered target discovery for a bacterial pathogen with a high medical need where no vaccine is currently available Evaxion’s proprietary ...
The primary objective is to evaluate VISTA as a biomarker to guide patient selection and treatment optimization for VISTA-targeted therapies where no stand...
The bridging study is a multicenter, open-label, Phase II study to evaluate the efficacy, safety and pharmacokinetics of tazemetostat for the treatment of ...
Uniting the Global Supply Chain: CPHI Barcelona serves as a vital platform for unrivalled networks and access to the global supply chain. It provides unpa...
Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”) announced a change of the Company’s name to Elutia Inc. The rebranding reflects the ...
“Ono has a strong and proven track record in developing antibody candidates in areas of need, including the development of the anti-PD-1 antibody Opd...
© 2026 Biopharma Boardroom. All Rights Reserved.
